Harel Insurance Investments & Financial Services Ltd. Has $1.40 Billion Position in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Harel Insurance boosted its Teva stake 19.2% to 44,951,773 shares (about 3.92% of Teva) valued at roughly $1.40 billion, making Teva the firm's largest holding (~12.1% of its portfolio).
• Analyst sentiment is mostly constructive — nine Buys vs one Sell with a consensus price target of $41.56 — and multiple brokers recently raised targets (UBS to $42, Scotiabank $40, Barclays $38), supporting buying interest.
• However, substantial insider selling occurred this quarter (1,086,339 shares valued at about $35.9 million, including large executive/director dispositions), which could temper sentiment despite upgrades.

Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 19.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 44,951,773 shares of the company's stock after acquiring an additional 7,255,083 shares during the quarter. Teva Pharmaceutical Industries comprises about 12.1% of Harel Insurance Investments & Financial Services Ltd.'s portfolio, making the stock its biggest holding. Harel Insurance Investments & Financial Services Ltd. owned approximately 3.92% of Teva Pharmaceutical Industries worth $1,402,945,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently modified their holdings of the stock. Grove Bank & Trust raised its holdings in shares of Teva Pharmaceutical Industries by 300.0% during the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company's stock worth $31,000 after buying an additional 750 shares in the last quarter. Cromwell Holdings LLC raised its holdings in shares of Teva Pharmaceutical Industries by 40.3% during the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company's stock worth $44,000 after buying an additional 629 shares in the last quarter. Rothschild Investment LLC raised its holdings in shares of Teva Pharmaceutical Industries by 97.0% during the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company's stock worth $55,000 after buying an additional 1,348 shares in the last quarter. JFS Wealth Advisors LLC raised its holdings in shares of Teva Pharmaceutical Industries by 257.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company's stock worth $56,000 after buying an additional 2,000 shares in the last quarter. Finally, LRI Investments LLC raised its holdings in shares of Teva Pharmaceutical Industries by 246.0% during the 3rd quarter. LRI Investments LLC now owns 2,813 shares of the company's stock worth $57,000 after buying an additional 2,000 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Barclays boosted their price target on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an "overweight" rating in a report on Friday, January 30th. Wall Street Zen cut Teva Pharmaceutical Industries from a "strong-buy" rating to a "hold" rating in a report on Saturday. Scotiabank boosted their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a "sector outperform" rating in a report on Thursday, January 29th. Finally, UBS Group boosted their price target on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a "buy" rating in a report on Thursday, April 30th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $41.56.

Trending Headlines about Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Analysts are lifting Teva’s fair value and reframing the investment case (higher fair value to $40.09), signaling improved Street confidence in R&D, biosimilars and capital allocation — a clear near‑term catalyst for demand. Read More.
• Positive Sentiment: Multiple brokerages have raised price targets recently (reports include increases up to $45), and Piper Sandler reiterated an Overweight — these upgrades and higher targets support buying interest and headline momentum. Read More.
• Positive Sentiment: Teva will present at the BofA Securities Health Care Conference on May 12 (EVP of R&D to speak). Management comments on pipeline, R&D progress or commercial execution there could produce a directional move. Read More.
• Neutral Sentiment: Street estimates remain constructive but not unanimous — consensus near‑term EPS estimates sit around ~$2.5–2.6 for the year, which frames valuation (current P/E in the mid‑20s). This keeps upside tied to execution and guidance.
• Negative Sentiment: Insider selling: EVP Christine Fox sold 21,258 shares (~25% reduction of her stake) at an average price ~$35.31; such insider dispositions can be read as a negative signal or simply routine liquidity. Read More.
• Negative Sentiment: Large insider sale: Director/executive Mark Sabag sold 144,180 shares (~64% reduction) at ~ $34.99 — a sizable disposition that may temper sentiment from analyst upgrades. Read More.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $35.86 on Wednesday. Teva Pharmaceutical Industries Ltd. has a 12-month low of $14.99 and a 12-month high of $37.35. The business has a 50-day simple moving average of $31.19 and a two-hundred day simple moving average of $29.57. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. The stock has a market cap of $41.24 billion, a PE ratio of 26.97, a PEG ratio of 3.42 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The business had revenue of $3.98 billion during the quarter. Analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Richard Daniell sold 17,295 shares of the stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $547,732.65. Following the completion of the sale, the executive vice president owned 85,755 shares of the company's stock, valued at approximately $2,715,860.85. This represents a 16.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Placid Jover sold 14,150 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $448,130.50. Following the completion of the sale, the insider directly owned 6,774 shares of the company's stock, valued at approximately $214,532.58. The trade was a 67.63% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 1,086,339 shares of company stock valued at $35,852,268. Corporate insiders own 0.54% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.